Pfizer will become the first firm to customize IBM's Watson for Drug Development, combining its proprietary data with licensed and publicly available data.
Thermo Fisher developed the NGS-based multi-marker assay in collaboration with Novartis and Pfizer to match lung cancer patients with targeted drugs.
The update includes several key initiatives such as a liquid biopsy database, a DoD-led longitudinal study, and NCI cloud collaborations with Amazon and Microsoft.
The companies discussed their plans to change the one-test, one-drug companion diagnostic paradigm at the Personalized and Precision Medicine conference this week.
The researchers identified off-target interaction with the protein CatD as a likely cause of eye damage observed as a side effect of some BACE1 inhibitors.
With genotypes for hundreds of thousands of individuals, investigators uncovered 15 loci linked to major depressive disorder in individuals with European ancestry.
The foundation, which was established by the American College of Medical Genetics and Genomics, will use the money to fund fellows' salaries and research.
Data from the meeting suggest that lung cancer patients with ALK-positive tumors may soon have two first-line options and more choices when their disease progresses.
By showing flexibility and requiring a CDx in the post-market setting, the agency hopes to encourage the development of a universal NGS test.
Building on the companies' existing relationship, the deal licenses KineMed's proteomics platform to the pharmaceuticals giant for CDx development.
In Science this week: genetic analysis of pollutant-tolerant fish, and more.
Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.
New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.
NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.